Published in TB and Outbreaks Week, August 1st, 2000
The vaccine is indicated in individuals one year of age and older for the prevention of group C meningococcal infection, which is a leading cause of meningitis.
NeisVac-C is one of a new generation of "conjugate" vaccines in which the body's immune system elicits a stronger, longer lasting antibody response across a wider age range than non-conjugate vaccines. The result is a higher level of protection against infectious diseases. This long-term protection in children...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.